InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 MXC partners with Epilepsy Action Australia 30 Oct 2018 11:57AM $0.056 $0.420 risen by 650%
$18 September Quarterly Activity and Cashflow Report 26 Oct 2018 11:37AM $0.056 $0.420 risen by 650%
$18 Notice of Annual General Meeting/Proxy Form 22 Oct 2018 4:32PM $0.066 $0.420 risen by 536.36%
$18 MGC Derma - CannaGlobal Transaction Update 19 Oct 2018 9:31AM $0.071 $0.420 risen by 491.55%
$18 Response to ASX Price and Volume Query 16 Oct 2018 6:35PM $0.079 $0.420 risen by 431.65%
$18 Trading Halt 16 Oct 2018 4:06PM $0.079 $0.420 risen by 431.65%
$18 Pause in Trading 16 Oct 2018 3:21PM $0.079 $0.420 risen by 431.65%
$18 CannEpil Authorised to Commence Australian Sales 11 Oct 2018 9:41AM $0.051 $0.420 risen by 723.53%
$18 Trading Halt 9 Oct 2018 9:25AM $0.051 $0.420 risen by 723.53%
$18 MGC Derma - CannaGlobal Transaction Update 4 Oct 2018 11:01AM $0.049 $0.420 risen by 757.14%
$18 Reinstatement to Official Quotation 27 Sep 2018 11:33AM $0.048 $0.420 risen by 775%
$18 Sale of MGC Derma to Strategic Partner Cannaglobal Canada 27 Sep 2018 11:32AM $0.048 $0.420 risen by 775%
$18 Suspension from Official Quotation 25 Sep 2018 10:19AM $0.048 $0.420 risen by 775%
$18 Contract Default Notice Issued To Varm Cosmo 25 Sep 2018 9:25AM $0.048 $0.420 risen by 775%
$18 Trading Halt 21 Sep 2018 9:42AM $0.048 $0.420 risen by 775%
$18 MXC Signs Major Distribution Agreement for GMP Products 6 Sep 2018 9:43AM $0.054 $0.420 risen by 677.78%
$18 Appendix 4E and Audited 2018 Financial Report 3 Sep 2018 8:05AM $0.055 $0.420 risen by 663.64%
$18 MXC to Commence Australian Dementia Trial with Notre Dame 27 Aug 2018 9:55AM $0.055 $0.420 risen by 663.64%
$18 Harvey Nichols Expands MGC Derma Distribution in the UK 8 Aug 2018 9:35AM $0.056 $0.420 risen by 650%
$18 Neurology & Epilepsy Expert Joins MXC Medical Advisory Board 31 Jul 2018 9:45AM $0.057 $0.420 risen by 636.84%
$18 June Quarterly Activity and Cashflow Report 30 Jul 2018 2:25PM $0.060 $0.420 risen by 600%
$18 Change of Director's Interest Notice - Appendix 3Y 18 Jul 2018 4:31PM $0.065 $0.420 risen by 546.15%
$18 Conversion of Performance Rights - Appendix 3B & VHL Shares 18 Jul 2018 4:30PM $0.065 $0.420 risen by 546.15%
$18 MXC Awarded GMP Certification & Manufacturing Licence 13 Jul 2018 9:42AM $0.063 $0.420 risen by 566.67%
$18 Trading Halt 11 Jul 2018 9:20AM $0.063 $0.420 risen by 566.67%

601 - 625 of 818 results

Page 25 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.